Literature DB >> 25019279

Investigating the economic burden of ALS in Greece: a cost-of-illness approach.

Kostas Athanasakis1, Ilias-Ioannis Kyriopoulos, Manthos Sideris, Michael Rentzos, John Evdokimidis, John Kyriopoulos.   

Abstract

The present study aims to investigate the economic burden of ALS per patient in Greece. A sample of 33 patients who were monitored in Aeginition University Hospital in Athens, a reference centre for ALS in Greece, was used for the calculations. According to the findings of this study the total annual cost per ALS patient in Greece was €7450. The direct cost was estimated at €4305 (or 57.8% of the total cost), while the indirect cost was €3145 (or 42.2% of the total cost). Medications, professional home help and cost due to work absenteeism were the leading components of total cost. In general, the aforementioned amount is considered substantial, albeit lower than the corresponding amount of other countries.

Entities:  

Keywords:  Cost-of-illness; amyotrophic lateral sclerosis; health economics

Mesh:

Year:  2014        PMID: 25019279     DOI: 10.3109/21678421.2014.932384

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  4 in total

Review 1.  Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.

Authors:  Alan Moore; Carolyn A Young; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

2.  The economic burden of amyotrophic lateral sclerosis: a systematic review.

Authors:  K Achtert; L Kerkemeyer
Journal:  Eur J Health Econ       Date:  2021-06-18

3.  Using telehealth in motor neuron disease to increase access to specialist multidisciplinary care: a UK-based pilot and feasibility study.

Authors:  Esther V Hobson; Wendy O Baird; Mike Bradburn; Cindy Cooper; Susan Mawson; Ann Quinn; Pamela J Shaw; Theresa Walsh; Christopher J McDermott
Journal:  BMJ Open       Date:  2019-10-22       Impact factor: 2.692

Review 4.  Cost-of-illness studies in rare diseases: a scoping review.

Authors:  Lidia García-Pérez; Renata Linertová; Cristina Valcárcel-Nazco; Manuel Posada; Inigo Gorostiza; Pedro Serrano-Aguilar
Journal:  Orphanet J Rare Dis       Date:  2021-04-13       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.